Advancing mRNA Therapeutics with Lipid Nanoparticles

Lipid nanoparticles (LNPs) have revolutionized the delivery of mRNA therapeutics, providing stability, targeted delivery, and protection against degradation. From COVID-19 vaccines to cancer immunotherapies and genome editing, these systems represent a transformative shift in medicine.

QS-21: A Promising Saponin Adjuvant for Enhancing Vaccine Efficacy

QS-21, a saponin-derived adjuvant extracted from the bark of the Quillaja saponaria tree, has emerged as a key player in the field of vaccine development. Recognized for its ability to enhance immune responses, QS-21 is increasingly being explored as a vital component in vaccine formulations aimed at improving immunogenicity and overall effectiveness.

The Importance of Quality Control to Aseptic Filling

Based on PIC/S Annex 1 “Manufacture of Sterile Medicinal Products”, it is particularly important to ensure the quality and safety of sterile medicinal products throughout their manufacturing process. QC has played an essential role in the control and reduction of contamination by microorganisms, particulates and endotoxins/pyrogens.

Amaran Biotech X Cytiva: Advanced Aseptic Processing Technology for Protein and New Modalities Workshop

Aseptic filling is the final production stage in the pharmaceutical industry and one of the most critical steps. However, the production process for proteins and new therapeutic modalities in aseptic filling faces numerous difficulties and challenges. To further advance the pharmaceutical industry and enhance the understanding of advanced aseptic filling processes among industry professionals and experts, Amaran and Cytiva will co-host the "Advanced Aseptic Processing Technology for Proteins and New Modalities" Workshop, scheduled to be held on Thursday, November 7, 2024, in Zhubei City.

Bioconjugation

Bioconjugation is a chemical process that forms a covalent link between two molecules, at least one of which is a biomolecule. This technique has revolutionized various fields, including medicine, diagnostics, and biotechnology.

【OkinawaTimes】Amaran Biotech 横浜で開催されるBioJapan 2024に初出展

【京都新聞】Amaran Biotech 横浜で開催されるBioJapan 2024に初出展

【福井新聞】Amaran Biotech 横浜で開催されるBioJapan 2024に初出展

【每日新聞】Amaran Biotech 横浜で開催されるBioJapan 2024に初出展

【Yahoo!Finance】Amaran Biotech Makes Its Debut at BioJapan 2024 in Yokohama

【Macau Business】Amaran Biotech Makes Its Debut at BioJapan 2024 in Yokohama

Amaran Biotech Makes Its Debut at BioJapan 2024 in Yokohama

Amaran Biotech, a leading Taiwanese CDMO (Contract Development & Manufacturing Organization) offering comprehensive pharmaceutical development and manufacturing solutions, is making its debut at BioJapan 2024 in Yokohama from October 9 to 11. The company is participating as part of Taiwan’s Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) delegation. Amaran Biotech will showcase its services at the Taiwan Pavilion (Booth No. B-56), including its vaccine adjuvant AB-801 (QS-21), drug substance manufacturing, drug product manufacturing, and stability study and analytical science services. Visitors are invited to meet with Amaran Biotech's representatives at the event.